Why the study?
How does the inclusion of a specialized cardiac conduction system in a computational model affect the simulated electrophysiological effects of dofetilide?
How does the inclusion of a specialized cardiac conduction system in a computational model affect the simulated electrophysiological effects of dofetilide?
Incorporating the specialized cardiac conduction system into computational ventricular models reveals significant differences in the simulated electrophysiological effects of dofetilide, emphasizing the need for structural heterogeneity in cardiac modeling.
Inclusion of specialized conduction system alters dofetilide effects on APD/QT in ventricular models; leaves open optimal structural detail for arrhythmia simulations.
The use of antiarrhythmic drugs is common to treat heart rhythm disorders. Computational modeling and simulation are promising tools that could be used to investigate the effects of specific drugs on cardiac electrophysiology. In this paper, we study the multiscale effects of dofetilide, a drug that blocks IKr, from cellular to organ level paying special attention to its effect on heart structures, in particular the specialized cardiac conduction system (CCS). We include a model of the CCS in a patient-specific anatomical ventricular model and study the drug effects in simulations with and without a CCS. Results confirmed the expected effects of dofetilide at cellular level, increasing the action potential duration, and at organ level, prolonging the QT segment. Notable differences are shown between models with and without the CCS on action potential duration distributions. These techniques show the importance of heart heterogeneity and the global effects of the interaction of drugs with cardiac structures.
No takes yet. Share an insight, caveat, or question.
Dux‐Santoy et al. (2011) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: